Seattle-based biotech firm Impel NeuroPharma closed its latest round of funding, bringing in $67.5 million to develop treatments for central nervous system disorders, such as migraines and Parkinson’s.
This is Impel’s largest fundraising round to date, following a $36 million round in December 2016.
Impel is known for its Precision Olfactory Delivery (POD) platform, which sends drugs into the nasal cavity with the goal of penetrating the blood-brain barrier and targeting the organ more directly than is possible with pills or injected drugs.
